Mayo Clinic's One-Person ALS Therapy Is Showing Early Promise

Mayo Clinic researchers have reported encouraging early results from an ALS therapy designed for exactly one person: a custom-built RNA drug that silences the faulty gene behind one man's rare inherited form of amyotrophic lateral sclerosis. According to the clinic's announcement, the patient's blood marker of nerve-cell injury fell by half during treatment, while his breathing, thinking and movement stayed stable or improved slightly. The study, published in the journal Med, is being held up as a proof of concept for a new model of medicine — treatments built from scratch around a single patient's DNA.

ALS progressively destroys the motor neurons that control voluntary movement, and the case centers on a mutation in a gene called CHCHD10. The faulty gene makes a protein that harms nerve cells and scrambles a second protein, TDP-43, that shows up in nearly every ALS case. Fewer than one in a hundred people with inherited ALS carry a CHCHD10 mutation, which is why no drug company would ever build a medicine for it — the patient population is far too small. This study asked a different question: what if the medicine only had to work for one person?

From diagnosis to a custom drug in three years

The man at the center of the study developed weakness in his right shoulder in 2020 and was diagnosed with ALS the following year, after genetic testing flagged the CHCHD10 mutation. The Jacksonville neurology team partnered with the nonprofit n-Lorem Foundation, which develops antisense medicines for ultrarare genetic diseases. Its scientists designed and screened more than 320 candidate molecules before picking a lead that precisely blocked the faulty gene's instructions. Between April 2024 and April 2025, the patient received six doses of the drug through injections into the fluid surrounding his spinal cord.

The response came fast. Levels of neurofilament light, a protein that leaks into the blood when nerve cells are damaged, returned to the normal range within three months and ended the year down by roughly half. His score on a standard ALS function scale, which tracks everyday movement and breathing, rose from 33 to 36 over the year — movement in the right direction for a disease that only moves one way. No serious side effects appeared, and the same experimental drug is now being tested in eight additional people who carry CHCHD10 mutations, as Alzforum reported. For comparison, antisense drugs aimed at far more common ALS mutations took a decade or more to develop; this one went from idea to injection in about three years.

The N-of-1 playbook

The treatment belongs to a class called antisense oligonucleotides, or ASOs: short synthetic strands of genetic material that latch onto the RNA copy of a gene and stop the harmful protein from being made. They do not rewrite a person's DNA the way gene editing does. The approach is experimental and was delivered under a single-patient research protocol run through the clinic's N-of-1 Therapeutics Program, which is trying to build a reusable framework — scientific, clinical and regulatory — for making individualized genetic medicines. The program's director, Margot Cousin, said cases like this one are how the field learns to do personalized treatment rigorously and fairly, with lessons that could eventually reach far beyond ultrarare disease.

This is not the first time genetic medicine has aimed small to learn big. A CRISPR-based cholesterol treatment showed a single gene-targeting dose can halve bad cholesterol for a year, and the broader science of precision therapy keeps finding that rare mutations are the clearest windows into common diseases. The clinic has deep roots in this territory: its researchers helped discover the most common inherited cause of ALS back in 2011, and one of those scientists, Rosa Rademakers, received the 2026 Breakthrough Prize in Life Sciences for the work.

Why one patient matters to everyone else

There are real limits here, and the researchers do not hide them. This ALS therapy is experimental research, not standard care, and a single patient cannot prove a drug works — in a disease as variable as ALS, short-term stability can happen on its own. The team's neurologist, Björn Oskarsson, noted that while about half of all ALS cases are thought to have a genetic cause, only a slice of those are currently suited to an antisense approach; other mutations may need entirely different tools such as gene editing. Scaling one-person drugs also raises hard questions about cost, access and who gets to be patient number one.

Still, the direction of travel is the story. Drug development has always been built for averages — one molecule, millions of patients, a decade of trials. This study ran the model in reverse: one genome, one molecule, three years. If the framework holds up as more single-patient cases accumulate, people with ultrarare conditions — the ones too few to justify a clinical trial — could one day have medicines built around them rather than waiting for a trial built around everyone. As MedicalXpress reported, researchers are already studying the patient's cells to understand exactly how silencing CHCHD10 changes the disease at the molecular level. For now, one man's stabilized symptoms are a signal: the era of the bespoke drug has quietly begun.